R&D Tax Credit Insights & Analysis

R&D Tax Credits for Controlled Groups: Aggregation and Allocation Strategies

Many U.S. companies operate through multiple entities—holding companies, LLCs, subsidiaries, partnerships—which often triggers related‑entity rules under federal and state tax codes when it comes to claiming the R&D tax credit. Under IRC § 41(f) and Treasury Regulation § 1.41‑6, the Internal Revenue Service treats all entities in a qualifying “controlled group” as a single taxpayer. That means qualified research expenses (QREs) must be aggregated across group members and the resulting credit allocated among them on a compliant basis. Proper aggregation can unlock significant credit amounts—whereas failure to apply the rules correctly may result in disallowed credits, penalties, interest, and lost audit defenses. This article walks you through the four‑step process of aggregation and allocation: defining controlled‑group status (parent‑subsidiary, brother‑sister, combined), performing ownership and attribution tests, aggregating QREs, computing credit (Regular vs ASC methods), allocating among entities and filing the updated 2025 Form 6765 (with business‑component disclosure rules). Real time planning tips, common pitfalls and state‑credit considerations round out the guide so multi‑entity taxpayers can maximize opportunity while staying audit‑ready.

IRS Delays Implementation of Form 6765 Changes for R&D Tax Credit Filers

On October 1, 2025, the IRS announced it is delaying the implementation of key Form 6765 changes (IR-2025-99). The extension gives taxpayers until March 31, 2026, to adapt to new reporting requirements for the R&D tax credit. Section G, which introduces detailed Business Component Reporting, remains optional for 2025 and will become mandatory in 2026 for most filers. The IRS also extended the 45-day transition period for perfecting refund claims through January 10, 2027. Businesses are encouraged to strengthen documentation and cross-functional processes now to stay compliant when the new standards take effect.

Landmark Tax Court Ruling Puts R&D Credits at Risk

The U.S. Tax Court’s December 2024 decision in Phoenix Design Group, Inc. v. Commissioner (T.C. Memo 2024-113) is a landmark case for engineering and professional services firms. The court denied R&D tax credit claims and upheld a 20% accuracy-related penalty under IRC §6662, citing insufficient contemporaneous documentation, lack of objective technical uncertainty, and no systematic process of experimentation required under §41(d). This ruling highlights the critical need for audit-ready documentation, activity-level time tracking, and applying the shrinking-back rule to protect R&D credit eligibility.

GENIUS Act and Its Role in Blockchain R&D Tax Credits

The GENIUS Act, signed into law in July 2025, establishes the first federal framework for stablecoins, requiring 1:1 dollar or Treasury backing, transparency, and regulated issuers. For blockchain and Web3 companies, this reduces uncertainty and aligns with the repeal of Section 174 amortization, which restores immediate expensing of U.S.-based R&D costs. Together, these changes create powerful opportunities to claim R&D tax credits. Startups may offset up to $500,000 in payroll taxes annually, while larger firms can recover a portion of development spend. Eligible activities include smart contract development, scalability experiments, custody integrations, DeFi protocols, and enterprise pilots. With regulatory clarity and financial incentives combined, the U.S. is now one of the most favorable jurisdictions globally for blockchain R&D.

Maximize R&D Tax Savings with IRS Rev. Proc. 2025-28 and OBBBA

IRS Rev. Proc. 2025-28 implements the One Big Beautiful Bill Act (OBBBA), restoring immediate §174A R&D expensing, simplifying §280C elections, and opening a refund window for 2022–2024 tax years. Small businesses can file amended or superseding returns to recover cash, while larger companies gain streamlined compliance with automatic accounting method changes. This guidance marks a turning point after TCJA’s capitalization rules, offering clarity, cash flow relief, and planning opportunities for innovative taxpayers.

Impact of IRC §280C Elections for R&D Tax Credit Claimants After OBBBA

The single guide to the Section 280C election after OBBBA: what the statute requires, Form 6765 filing mechanics, Schedule M-1 and M-3 treatment, the TCJA years, and when the election is worth making.

Debunking Section 174 Amortization Myths: Avoid R&D Tax Pitfalls

The One Big Beautiful Bill Act (OBBBA), signed into U.S. law on July 4, 2025, repeals Section 174 amortization for domestic R&D expenses, restoring immediate expensing starting in 2025. This change boosts cash flow, strengthens the value of Section 41 R&D tax credits, and supports U.S. businesses investing in innovation. But myths are spreading—about retroactive refunds, foreign R&D, software development, audits, and double-dipping under Section 280C. In this blog, Strike Tax Advisory debunks the top misconceptions, explains who qualifies for retroactive expensing (including the $31M small business threshold), and shows how startups and established companies can maximize credits, deductions, and hiring potential under OBBBA. If you’re searching for clear answers on “OBBBA Section 174 repeal,” “R&D tax credit myths 2025,” or “how to claim retroactive R&D deductions,” this guide breaks it down step by step.

The One Big Beautiful Bill Act (OBBBA) and the R&D Tax Credit

The U.S. House has passed the One Big Beautiful Bill Act (OBBBA), officially repealing Section 174 amortization and restoring immediate expensing for domestic R&D costs. This landmark change means small businesses (with under $31 million in annual gross receipts) could retroactively amend 2022-2024 tax returns to claim full deductions and receive refunds for previously amortized R&D expenses. Larger businesses can accelerate remaining deductions in 2025 and 2026. Foreign R&D costs must still be amortized over 15 years. With immediate expensing back, the Section 41 R&D Tax Credit becomes more valuable, unlocking significant cash flow and refund opportunities for innovative companies. The retroactive election window closed on July 6, 2026; open year credit claims and the catch-up deduction remain available.

Senate Approves OBBBA with Section 174 R&E Relief

The U.S. Senate has passed the One Big Beautiful Bill Act (OBBBA), delivering retroactive Section 174 R&E tax relief for small and medium-sized enterprises (SMEs). This landmark legislation allows qualifying businesses to immediately expense domestic research and experimental costs back to 2022, potentially unlocking millions in tax savings and boosting innovation. The bill now moves to the House of Representatives, where its retroactive relief provisions will be debated. SMEs are encouraged to consult tax experts, monitor legislative updates, and use StrikeTax’s R&D Tax Credit Calculator to maximize benefits. For ongoing updates and expert guidance, visit StrikeTax.com.

Section 174 Repeal: Big Win for SMEs in Senate Tax Reform

The Senate’s latest tax reform proposal includes a potential repeal of Section 174 amortization, offering SMEs the opportunity for immediate expensing of domestic R&D costs and retroactive tax benefits if enacted. This blog explains what will change, how SMEs can prepare, and what to watch for as the bill moves through Congress. Stay informed and ready to maximize your R&D tax savings if the new law is passed.

Pending 2025 Tax Bill Promises Section 174 Repeal

2025 tax bill draft document with Section 174 repeal highlighted for R&D tax relief.

2025 IRS Form 6765 Updates: Maximize R&D Tax Credits

The 2025 IRS Form 6765, used to claim R&D tax credits, introduces stricter reporting requirements.